Research Topic

Role of SRS/SBRT in Oligometastatic Disease

  • Submission closed.

About this Research Topic

Oligometastatic disease represents an intermediate state between the early localized disease and widespread metastatic malignancy. Some patients with oligometastatic disease, treated by ablative treatments to all sites of metastatic disease, can achieve long disease-free survival and sometimes cure. ...

Oligometastatic disease represents an intermediate state between the early localized disease and widespread metastatic malignancy. Some patients with oligometastatic disease, treated by ablative treatments to all sites of metastatic disease, can achieve long disease-free survival and sometimes cure. Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) are accepted treatment options for these patients, achieving high rates of local control. While most of the studies report outcomes of SBRT for solitary oligometastasis, patients with oligometastatic disease might present multiple concurrent lesions either in the same organ or in neighboring organs. There are few studies addressing the role of SBRT in patients with multiple concurrent oligometastases. Furthermore, these patients likely recur either in the same organ or at distance. Therefore, the need for retreatment with SBRT might be required. There remains a dearth of data regarding the re-irradiation after prior SBRT, toxicity and dose volume constraints.

Particularly as it related to significant improvements in systemic therapies (including immunotherapies), it is likely that the number of patients presenting with induced oligometastases will increase. While targeted, immune therapies and SBRT are increasingly used in patients with oligometastatic disease, their sequencing, interaction, and toxicities have not been studied and are poorly understood.

We are inviting submission of papers reporting treatment options, outcomes, and toxicities in patients with oligometastatic disease, especially in the context of multiple oligometastases, re-irradiation after prior SBRT and for patients undergoing new systemic treatments.


Keywords: Oligometastases, SBRT, repeat SBRT, interaction with systemic treatments


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top
);